About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  About Us
  Research & Development
  Branded Formulations
  Financial Results
  - Q3FY18 Results
  - Investor Call Invite
  - Investor Presentation
  - Chairman's Speech 2017
  - Annual Reports

 Annual Report 2017

Annual Report 2017

  - Biocon Profile
  - CMD Profile
  - Video Gallery


Biocon Malaysia


  Biocon Academy


  Facilities Virtual Tour

Biocon Ltd., Asia's premier biopharmaceutical company, is committed to ensure a global right to healthcare by addressing the worldwide need for safe, effective and affordable biotherapeutics.

We have harnessed the power of biotechnology through affordable innovation to enhance access to new and differentiated therapies for diseases that are chronic, where medical needs are largely unmet.

The Company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in India and other emerging markets. Today, we are India's largest and fully-integrated biopharmaceutical company that develops, manufactures and supplies advanced, life-saving biopharmaceuticals for diabetes, cancer and autoimmune conditions at price points that make them affordable and thus accessible.

As an innovation-led organization focused on providing affordable access, we have leveraged our inherent strengths in advanced science to develop, manufacture and deliver a rich portfolio of Small Molecules APIs & Formulations and Complex Biologics - both Novels and Biosimilars - including Monoclonal Antibodies (MAbs), rh-insulin and Insulin Analogs.

Our global scale capacities for manufacturing high quality, affordable biologics have positioned us as the world's fourth largest insulins producer, enabling us to address the growing needs of diabetes patients across the globe. As one of the leading oncology companies in India, we have brought safe, efficacious and affordable medicines for cancer to cater to the needs of patients, caregivers and medical practitioners in the country. br>


Biocon Q3FY18 Performance Highlights by Kiran Mazumdar-Shaw, CMD, Biocon

Kiran Mazumdar-Shaw addresses bioconites on approval of Biosimilar Trastuzumab by USFDA

Biocon: Engaged in Affordable
Innovation for Global Impact
Stock Update


Company Announcements


Jan. 29, 2018 
 Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine

Jan. 24, 2018 
 Biocon Q3FY18 Revenue at Rs 1092 Crore; EBITDA at Rs 256 Crore; Net Profit at Rs 92 Crore

Jan. 18, 2018 
 Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars

Dec. 29, 2017 
 Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs

Dec. 13, 2017 
 Biocon´s Clarification post  media reports on “Biocon  on the FDA list for not  paying facility fee”. Biocon  has paid Facility Fee for its  API facility to USFDA in Sep  2017

Dec. 01, 2017 
 U.S. FDA Approves Mylan  and Biocon´s OgivriTM the  First Biosimilar for  Trastuzumab, for the  Treatment of HER2­Positive  Breast and Gastric Cancers

  Media Coverage  

 Dec 2017:  U.S. FDA Approves  Mylan and Biocon´s OgivriTM  the First Biosimilar for  Trastuzumab, for the  Treatment of HER2−Positive  Breast and Gastric Cancers

 July 2017:   Biocon Featured in ´Outlook Business  Outperformers´ special edition.








Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved